AliveCor has reported study results that showed the accuracy of the company's iPhone-based smartphone ECG device.

The study compared the iPhone-based event recorder’s Lead I to Lead I from a conventional 12-lead ECG.

The study found that the iPhone-based device is used as a clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.

Twelve-lead ECGs (Mac5500, GE Healthcare) with gel-based electrodes and Lead I ECGs (AliveCor ECG, AliveCor) were recorded in 67 patients.

Five patients with pacemakers had the iPhone placed directly on the chest to record a V3-V4 rhythm strip and were identified with pacing spike artifacts.

In 62 patients, the QRS morphology was found to be same between the two devices and the mean/SD of the R-wave amplitudes for the standard and iPhone recordings were 0.77/0.24 (mV) and 0.78/0.24 (mV), P<0.0001 respectively.

AliveCor founder and chief medical officer David Albert said the company’s technology, which upon anticipated marketing approval will improve early diagnosis of arrhythmias and overall public awareness of health metrics.

"We envision that our technology will significantly benefit patients who need consistent and more convenient monitoring," Albert added.